AU2018229920B2 - Use of vitamin composition in preparing drug for preventing, treating, or delaying Alzheimer's disease - Google Patents

Use of vitamin composition in preparing drug for preventing, treating, or delaying Alzheimer's disease Download PDF

Info

Publication number
AU2018229920B2
AU2018229920B2 AU2018229920A AU2018229920A AU2018229920B2 AU 2018229920 B2 AU2018229920 B2 AU 2018229920B2 AU 2018229920 A AU2018229920 A AU 2018229920A AU 2018229920 A AU2018229920 A AU 2018229920A AU 2018229920 B2 AU2018229920 B2 AU 2018229920B2
Authority
AU
Australia
Prior art keywords
vitamin
parts
vitamins
composition
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018229920A
Other languages
English (en)
Other versions
AU2018229920A1 (en
Inventor
Mingdong Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zensun Shanghai Science and Technology Ltd
Original Assignee
Zensun Shanghai Science and Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zensun Shanghai Science and Technology Ltd filed Critical Zensun Shanghai Science and Technology Ltd
Publication of AU2018229920A1 publication Critical patent/AU2018229920A1/en
Application granted granted Critical
Publication of AU2018229920B2 publication Critical patent/AU2018229920B2/en
Priority to AU2024202678A priority Critical patent/AU2024202678A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2018229920A 2017-03-07 2018-02-24 Use of vitamin composition in preparing drug for preventing, treating, or delaying Alzheimer's disease Active AU2018229920B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024202678A AU2024202678A1 (en) 2017-03-07 2024-04-24 Use of vitamin composition in preparing drug for preventing, treating, or delaying Alzheimer's disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710131111.X 2017-03-07
CN201710131111.XA CN108567792A (zh) 2017-03-07 2017-03-07 一种治疗阿尔茨海默病的复合维生素组合物
PCT/CN2018/077107 WO2018161808A1 (zh) 2017-03-07 2018-02-24 维生素组合物在制备用于预防、治疗或延迟阿尔茨海默病的药物中的用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024202678A Division AU2024202678A1 (en) 2017-03-07 2024-04-24 Use of vitamin composition in preparing drug for preventing, treating, or delaying Alzheimer's disease

Publications (2)

Publication Number Publication Date
AU2018229920A1 AU2018229920A1 (en) 2019-10-03
AU2018229920B2 true AU2018229920B2 (en) 2024-02-08

Family

ID=63448062

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018229920A Active AU2018229920B2 (en) 2017-03-07 2018-02-24 Use of vitamin composition in preparing drug for preventing, treating, or delaying Alzheimer's disease
AU2024202678A Pending AU2024202678A1 (en) 2017-03-07 2024-04-24 Use of vitamin composition in preparing drug for preventing, treating, or delaying Alzheimer's disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024202678A Pending AU2024202678A1 (en) 2017-03-07 2024-04-24 Use of vitamin composition in preparing drug for preventing, treating, or delaying Alzheimer's disease

Country Status (9)

Country Link
US (2) US11464797B2 (enExample)
EP (2) EP4461361A3 (enExample)
JP (3) JP7169285B2 (enExample)
CN (2) CN108567792A (enExample)
AU (2) AU2018229920B2 (enExample)
BR (1) BR112019018652A2 (enExample)
CA (1) CA3054972A1 (enExample)
ES (1) ES2989651T3 (enExample)
WO (1) WO2018161808A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7442874B2 (ja) * 2019-08-02 2024-03-05 シャンハイ、レイジング、ファーマシューティカル、カンパニー、リミテッド アルツハイマー病における標的としてのｔｐｋの使用
KR102275981B1 (ko) * 2020-03-31 2021-07-13 고려은단주식회사 섬쑥부쟁이 추출물과 비타민 b 복합체의 혼합물을 포함하는 인지기능 개선용 조성물
AU2022464309A1 (en) * 2022-06-22 2025-01-23 Biomedical Research Group Inc. Prophylactic drug and therapeutic drug for diabetes-associated dementia
CN119055674B (zh) * 2024-11-06 2025-02-18 中国医学科学院北京协和医院 一种可改善认知的组合物及其在阿尔茨海默病防治中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110280852A1 (en) * 2010-05-13 2011-11-17 Nitromega Corp. Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline
US20130136800A1 (en) * 2010-03-31 2013-05-30 Vegenat, S.A. Enteral Or Oral Food Product Intended, In Particular, For nutrition And For The Prevention And Improvement Of Neurological Alterations, Neurodegenerative Alterations or Cognitive Disorders
US20140274938A1 (en) * 2011-10-31 2014-09-18 N.V. Nutricia Improving recognition
US20150044138A1 (en) * 2012-03-02 2015-02-12 N.V. Nutricia Method for improving functional synaptic connectivity

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626884A (en) 1995-08-18 1997-05-06 Lockett; Curtis G. Treatment of sickle cell disease
DE69930746T2 (de) 1998-06-10 2007-03-15 Crum, Albert B. Vorbeugender und therapeutischer nahrungsmittelzusatz zur schaffung/erhaltung einer die gesundheit schützenden darmmikroflora und zur stärkung des immunsystems
WO2003082339A1 (en) 2002-03-22 2003-10-09 Doc's Guide, Inc. Multivitamin and mineral nutritional supplement
CA2583972A1 (en) 2004-10-14 2006-10-19 Adventures Plus Pty Ltd A method for the treatment of gastrointestinal and other disorders with an admixture of vitamins and minerals
US20110275591A1 (en) * 2004-12-01 2011-11-10 Concourse Health Sciences Llc Cocktail for modulation of alzheimer's disease
US20060148727A1 (en) * 2004-12-01 2006-07-06 Curt Hendrix Folate based composition for neurological and cognitive applications
NZ582329A (en) * 2007-06-26 2012-09-28 Nutricia Nv Improving memory in subjects with mini-mental state examination of 24-26
US9763989B2 (en) * 2007-08-03 2017-09-19 Shaklee Corporation Nutritional supplement system
JP4206428B1 (ja) * 2008-06-09 2009-01-14 正樹 今川 認知症を処置するための組成物及びその利用
KR20110004691A (ko) * 2009-07-08 2011-01-14 대한민국(농촌진흥청장) 뇌기능 개선효과를 가지는 붉나무 추출물을 포함하는 약학조성물 및 건강식품조성물
WO2012012682A2 (en) 2010-07-22 2012-01-26 Zishan Haroon Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution
KR20130015932A (ko) * 2011-08-05 2013-02-14 연세대학교 산학협력단 저용량의 치아졸리딘다이온을 포함하는 알츠하이머 병 치료용 약학조성물
EP2882304A1 (en) * 2012-08-07 2015-06-17 Buck Institute For Research On Aging Multi-component formulation for improving neurological function
WO2014026161A1 (en) * 2012-08-10 2014-02-13 Aquavit Pharmaceuticals, Inc. Vitamin supplement compositions for injection
CN104337813A (zh) 2013-07-23 2015-02-11 上海泽生科技开发有限公司 使用维生素b组合物促进胃肠系统动力的方法
CN104256652A (zh) 2014-10-08 2015-01-07 李明刚 一种口服复合维生素纳米脂质体
CN104922164B (zh) * 2014-12-12 2020-06-02 中国医科大学 一种治疗阿尔茨海默病的药物复合制剂
CN111803514A (zh) * 2015-06-12 2020-10-23 上海泽生科技开发股份有限公司 使用复合维生素b、c组合物促进胃肠系统动力的方法
CN104856048A (zh) 2015-06-18 2015-08-26 安徽医联大成医药科技有限公司 一种促进肠胃蠕动的食品配方及其制备方法
CN108079008A (zh) * 2016-11-23 2018-05-29 上海泽生科技开发股份有限公司 促进胃肠系统动力的复合维生素组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130136800A1 (en) * 2010-03-31 2013-05-30 Vegenat, S.A. Enteral Or Oral Food Product Intended, In Particular, For nutrition And For The Prevention And Improvement Of Neurological Alterations, Neurodegenerative Alterations or Cognitive Disorders
US20110280852A1 (en) * 2010-05-13 2011-11-17 Nitromega Corp. Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline
US20140274938A1 (en) * 2011-10-31 2014-09-18 N.V. Nutricia Improving recognition
US20150044138A1 (en) * 2012-03-02 2015-02-12 N.V. Nutricia Method for improving functional synaptic connectivity

Also Published As

Publication number Publication date
JP2020509072A (ja) 2020-03-26
US20200030358A1 (en) 2020-01-30
US20230248756A1 (en) 2023-08-10
JP2023011769A (ja) 2023-01-24
CA3054972A1 (en) 2018-09-13
AU2024202678A1 (en) 2024-05-16
JP2025024089A (ja) 2025-02-19
CN108567792A (zh) 2018-09-25
JP7169285B2 (ja) 2022-11-10
EP3593805A1 (en) 2020-01-15
US11464797B2 (en) 2022-10-11
BR112019018652A2 (pt) 2020-04-07
CN110520135A (zh) 2019-11-29
ES2989651T3 (es) 2024-11-27
EP4461361A3 (en) 2025-01-01
EP4461361A2 (en) 2024-11-13
EP3593805A4 (en) 2020-10-07
WO2018161808A1 (zh) 2018-09-13
AU2018229920A1 (en) 2019-10-03
EP3593805B1 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
US20230248756A1 (en) Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease
Geisler et al. DNP, mitochondrial uncoupling, and neuroprotection: A little dab'll do ya
McInnes Mitochondrial-associated metabolic disorders: foundations, pathologies and recent progress
Zangara The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease
Pei et al. Directly and indirectly targeting the glycine modulatory site to modulate NMDA receptor function to address unmet medical needs of patients with schizophrenia
CA2766282C (en) Inhibitors of carnitin-palmitoyl-transferase-1 for the treatment and prevention of disorders caused by delipidation of neural tissue
Al-Jarrah et al. Endurance exercise training protects against the upregulation of nitric oxide in the striatum of MPTP/probenecid mouse model of Parkinson's disease
AU2002250942A1 (en) Compositions of biochemical compounds involved in bioenergy metabolism of cells
EP1368017A2 (en) Compositions of biochemical compounds involved in bioenergy metabolism of cells and method of use
Harati et al. Selective cholinergic lesions in the rat nucleus basalis magnocellularis with limited damage in the medial septum specifically alter attention performance in the five-choice serial reaction time task
Li et al. Theacrine, a purine alkaloid derived from Camellia assamica var. kucha, ameliorates impairments in learning and memory caused by restraint-induced central fatigue
Wei et al. Current situation and challenge of exogenous 3-hydroxybutyrate derived from polyhydroxyalkanoates for elderly health: A review
Liu et al. Insights on neuropharmacological benefits and risks: Aconitum carmichaelii Debx.
CN104582730B (zh) 一种提高线粒体代谢机能的方法及应用
CN103040905A (zh) 雪灵芝或其提取物在制备抗衰老的药物或保健食品中的用途
Kahale et al. To determine the Effect of Berberine on 6-OHDA induced memory impairment in Parkinson’s disease in rodents
Archer et al. Pharmacogenomics and personalized medicine in Parkinsonism
Atabilen et al. Could the ketogenic diet offer hope in management of neurological diseases?
Agrawal et al. Evaluation of Hordenine’s Therapeutic Potential in Alzheimer’s Disease-induced Cognitive and Oxidative Impairments
Hamed Parkinson's Disease: Molecular Mechanisms and Treatment Strategies.
Cheng et al. Potential benefits of vitamin D on brain pathologies and cognitive function in metabolic syndrome: evidence from in vivo and clinical studies
Zhang et al. No effect of pyrroloquinoline quinone on mouse body weight and energy metabolism with the concomitant increase in mitochondrial biogenesis and antioxidant ability
Moreira Inhibiting COMT in a mouse model of Parkinson's disease: a trial of Tolcapone in VMAT2-deficient mice
Showemimo Vitamin B12 Deficiency Does Not Stimulate Amyloid-beta Toxicity in a Ceanorhabditis elegans Model of Alzheimer’s Disease
Terpstra Purine nucleoside mediated neuroprotection in the 6-hydroxydopamine rodent model of Parkinson's disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)